IRIS

DE LAURENTIIS, MICHELINO

DE LAURENTIIS, MICHELINO  

DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA  

Mostra records
Risultati 1 - 20 di 294 (tempo di esecuzione: 0.036 secondi).
Titolo Tipologia Data di pubblicazione Autore(i) File
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 1.5 Abstract in rivista 2007 G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies 1.5 Abstract in rivista 2002 DE LAURENTIIS, Michelino; Arpino, Grazia; E., Massarelli; A., Ruggiero; Carlomagno, Chiara; G., Tortora; F., Ciardiello; Ar, Bianco
IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE. 2.1 Contributo in volume (Capitolo o Saggio) 2003 DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino
Manuale di Oncologia Clinica 2.1 Contributo in volume (Capitolo o Saggio) 1996 Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo
Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. 1.1 Articolo in rivista 2012 Giordano, A; Gao, H; Anfossi, S; Cohen, E; Mego, M; Lee, Bn; Tin, S; DE LAURENTIIS, Michelino; Parker, Ca; Alvarez, Rh; Valero, V; Ueno, Nt; DE PLACIDO, Sabino; Mani, Sa; Esteva, Fj; Cristofanilli, M; Reuben, Jm
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. 1.1 Articolo in rivista 2007 Giuseppe Di, Lorenzo; Riccardo, Autorino; DE LAURENTIIS, Michelino; Valeria, Forestieri; Carmela, Romano; Antonella, Prudente; Francesco, Giugliano; Ciro, Imbimbo; Vincenzo, Mirone; DE PLACIDO, Sabino
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. 1.1 Articolo in rivista 2006 Ciardiello, F; Troiani, T; Caputo, F; DE LAURENTIIS, Michelino; Tortora, G; Palmieri, Giovannella; De Vita, F; Diadema, Mr; Orditura, M; Colantuoni, G; Gridelli, C; Catalano, G; DE PLACIDO, Sabino; Bianco, A. R.
Neural network analysis for evaluating cancer risk in thyroid nodules with an indeterminate diagnosis at aspiration cytology: identification of a low-risk subgroup. 1.1 Articolo in rivista 2004 Antonio M., Ippolito; DE LAURENTIIS, Michelino; Giacomo L., La; Antonio, Eleuteri; Roberto, Tagliaferri; DE PLACIDO, Sabino; Riccardo, Vigneri; Antonino, Belfiore
Differential immunohistochemical detection of transforming growth factor , amphiregulin and CRIPTO in human normal and malignant breast tissues. 1.1 Articolo in rivista 1996 Panico, L.; D'Antonio, A.; Salvatore, G.; Mazza, E.; Tortora, Giampaolo; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Giordano, T.; Merino, M.; Salomon, D. S.; Gullick, W. J.; Pettinato, Guido; Bianco, A. R.; Ciardiello, F.
Prognosis of chronic myelomonocytic leukemia. 1.1 Articolo in rivista 1996 L., Catalano; S., Improta; DE LAURENTIIS, Michelino; S., Molica; I., Majolino; P., Musto; A., Fragasso; DE PLACIDO, Sabino; Rotoli, Bruno
Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. 1.1 Articolo in rivista 2004 Giuseppe Di, Lorenzo; Carmine, Pizza; Riccardo, Autorino; DE LAURENTIIS, Michelino; Ombretta, Marano; Adele, D'Alessio; Cancello, Giuseppe; Vincenzo, Altieri; Tortora, Giampaolo; Sisto, Perdonà; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. 1.1 Articolo in rivista 1998 G., Fontanini; DE LAURENTIIS, Michelino; S., Vignati; S., Chinè; M., Lucchi; V., Silvestri; A., Mussi; DE PLACIDO, Sabino; Tortora, Giampaolo; Bianco, ANGELO RAFFAELE; W., Gullick; C. A., Angeletti; G., Bevilacqua; Ciardiello, Fortunato
HER-2/neu receptor in prostate cancer development and progression to androgen independence. 1.1 Articolo in rivista 2004 Giuseppe Di, Lorenzo; Riccardo, Autorino; DE LAURENTIIS, Michelino; Luca, Cindolo; Massimo, D'Armiento; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. 1.1 Articolo in rivista 1995 Carlomagno, Chiara; Perrone, F.; Lauria, R.; DE LAURENTIIS, Michelino; Gallo, C.; Morabito, A.; Pettinato, Guido; Panico, L.; Bellelli, T.; Apicella, A.; Putrella, G.; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. 1.1 Articolo in rivista 2003 Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T; ATAC Trialists', Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Carlomagno, Chiara
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 1.1 Articolo in rivista 1996 Ciardiello, Fortunato; Damiano, Vincenzo; Bianco, Roberto; C., Bianco; G., Fontanini; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; J., Mendelsohn; Bianco, ANGELO RAFFAELE; Tortora, Giampaolo
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. 1.1 Articolo in rivista 2008 Cancello, G.; Montagna, E.; D'Agostino, D.; Giuliano, Mario; Giordano, A.; Di Lorenzo, G.; Plaitano, M.; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. 1.1 Articolo in rivista 2011 Davies, C; Godwin, J; Gray, R; Clarke, M; Cutter, D; Darby, S; Mcgale, P; Pan, Hc; Taylor, C; Wang, Yc; Dowsett, M; Ingle, J; Peto, R; Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. 1.1 Articolo in rivista 2007 Cuzick, J; Ambroisine, L; Davidson, N; Jakesz, R; Kaufmann, M; Regan, M; Sainsbury, R; LHRH agonists in Early Breast Cancer Overview, Group; DE LAURENTIIS, Michelino
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. 1.1 Articolo in rivista 2005 Early Breast Cancer Trialists' Collaborative, Group; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino